Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib with Chemotherapy for Relapsed/Refractory Acute Leukemias
NCT00410423Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jan 2006
- Primary completion
- May 2013
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of bortezomib in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) (3 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Dose Limiting Toxicity and Complete Response Rate up to 7 years. Started Jan 2006; status: completed.
02
Drugs
bortezomib
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00410423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00410423.